You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Estimating the Treatment Effects of Multiple Drug Combinations on Multiple Outcomes in Hypertension
Code for paper "Estimating the Treatment Effects of Multiple Drug Combinations on Multiple Outcomes in Hypertension"
Introduction
Hypertension poses a significant global health challenge, and its management is often complicated by the complexity of treatment strategies involving multiple drug combinations and the need to consider multiple outcomes. Traditional treatment effect estimation (TEE) methods struggle to address this complexity, as they typically focus on binary treatments and single outcomes. To overcome these limitations, we introduce METO, a novel framework designed for TEE in the context of multiple drug combinations and multiple outcomes. METO employs a multi-treatment encoding mechanism to effectively handle various drug combinations and their sequences, and differentiates between effectiveness and safety outcomes by explicitly learning the outcome type when predicting the treatment outcomes. Furthermore, to address confounding bias in outcome prediction, we employ an inverse probability weighting method tailored for multiple treatments, assigning each patient a balance weight derived from their propensity score against different drug combinations. Our comprehensive evaluation using a real-world patient dataset demonstrates that METO outperforms existing TEE methods, with an average improvement of 5.0% in area under the precision-recall curve and 6.4% in influence function-based precision of estimating heterogeneous effects. A case study demonstrates the effectiveness of our method in comprehensive treatment effect assessment, showcasing its potential for personalized treatment recommendations and informed hypertension management.
Dataset
The data we use is from MarketScan Commercial Claims and Encounters (CCAE) and includes approximately 130 million patients from 2012 to 2021. Access to the MarketScan data analyzed in this manuscript is provided by the Ohio State University. The dataset is available at https://www.merative.com/real-world-evidence.
Data structures
Cohort
Column
Description
Note
ENROLID
Patient enroll ID
Unique identifier for each patient
Index_date
The date of the first hypertension encounter
i.e., min (ADMDATE [1st hypertension admission date for the inpatient records], SVCDATE [1st hypertension service date for the outpatient records])